Ozmosi | Josamycin Drug Profile

Product Description

Mechanisms of Action: 50S Ribosomal Subunit Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Indications: None

Known Adverse Events: None

Company: Guilin Pharmaceutical Co., Ltd.
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Obstetric Labor, Premature

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
CTR20241412	CTR20241412	N/A	Completed	Epididymitis\|Maxillary Sinusitis\|Chronic Periodontitis\|Pyoderma\|Pneumonia\|Sialadenitis\|Enteritis\|Scarlet Fever\|Respiratory Tract Infections\|Mastitis\|Burns Unspecified\|Dacryocystitis\|Surgical Wound Infection\|Tonsillitis\|Pharyngitis\|Lymphadenitis\|Otitis Media, Suppurative\|Bronchitis, Chronic\|Pericoronitis	2024-07-16		2025-04-29	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
NCT00718705	PREMYC	P3	Completed	Obstetric Labor, Premature	2011-09-01		2019-03-18	Treatments

Recent News Events

Date	Type	Title
04/17/2024	PubMed	Antimicrobial resistance of genital mycoplasmas recovered from nonpregnant women in Greece: trends over the last 15 years.
04/01/2024	PubMed	Study on Drug Resistance to Treatment for Ureaplasma Urealyticum Infections in the Female Genital Tract.
03/13/2024	PubMed	Dispersive Solid-Phase Extraction and Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry-A Rapid and Accurate Method for Detecting 10 Macrolide Residues in Aquatic Products.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Josamycin

Alternative Names: josamycin Clinical Status: Inactive Latest Update: 2024-04-17 Latest Update Note: PubMed Publication